Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Treat-and-Extend vs PRN for Center-involved Diabetic Macular Edema (Real-world Study)
ChiCTR2500109606Phase 4Not yet recruiting
- Sponsor
- Hebei Eye Hospital
- Start
- Sep 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of aflibercept in diabetic macular edema (DME) (2 arms), sponsored by Hebei Eye Hospital. Primary endpoint: Mean change in BCVA at 12 months. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR2500109606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109606.